Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Purchases 10,000 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were purchased at an average cost of $5.02 per share, for a total transaction of $50,200.00. Following the transaction, the chief executive officer now directly owns 2,285,731 shares of the company’s stock, valued at approximately $11,474,369.62. The trade was a 0.44 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Friday, February 28th, Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock. The stock was acquired at an average cost of $4.76 per share, with a total value of $47,600.00.
• On Tuesday, February 25th, Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock. The shares were acquired at an average price of $4.46 per share, for a total transaction of $44,600.00.

Vanda Pharmaceuticals Price Performance

Shares of VNDA opened at $4.91 on Friday. Vanda Pharmaceuticals Inc. has a one year low of $3.71 and a one year high of $6.75. The company has a market cap of $286.33 million, a PE ratio of -15.34 and a beta of 0.74. The stock has a 50-day moving average of $4.60 and a 200-day moving average of $4.79.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The firm had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. Analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Mackenzie Financial Corp bought a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth about $240,000. Squarepoint Ops LLC boosted its stake in Vanda Pharmaceuticals by 186.4% during the 4th quarter. Squarepoint Ops LLC now owns 71,131 shares of the biopharmaceutical company’s stock valued at $341,000 after purchasing an additional 46,293 shares during the last quarter. Two Sigma Advisers LP increased its holdings in Vanda Pharmaceuticals by 11.2% during the 4th quarter. Two Sigma Advisers LP now owns 156,300 shares of the biopharmaceutical company’s stock worth $749,000 after purchasing an additional 15,700 shares in the last quarter. Two Sigma Investments LP increased its holdings in Vanda Pharmaceuticals by 94.7% during the 4th quarter. Two Sigma Investments LP now owns 199,460 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 97,017 shares in the last quarter. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Vanda Pharmaceuticals in the fourth quarter worth approximately $120,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on VNDA. HC Wainwright boosted their price target on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.